The global Pneumonia Vaccine Market is estimated to reach USD xx million by 2025 and is anticipated to grow at a CAGR of xx% during the forecast period, according to a comprehensive study added by Report Ocean,
The report offers an in-depth analysis of major driving factors, segments, regions & countries and key players in the market. Moreover, the report also outlines the competitive scenarios across different geographies along with key developments which include mergers and acquisitions, new product or services development, R&D activities, thus giving insights to the market players about the major regions gaining traction.
Request a Sample copy of Pneumonia Vaccine market report @ https://www.reportocean.com/industry-verticals/sample-request?report_id=43233
Growth Factors and Restraints
The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high costs associated with development of such vaccines restrain the market growth. Development of protein-based combination pneumococcal vaccines is expected to offer lucrative opportunities for the expansion of this market during the forecast period.
The worldwide Pneumonia Vaccine market research report provides a deep-dive analysis of the present market situation and future market trends. The analysis provided in the report help the manufacturers, companies, service providers, etc. as a major guiding factor for decision making and analyzing the current and future market situations. The report also analyzes the major players operating in the market.
List of major players operating in the Pneumonia Vaccine market include:
Glaxosmithkline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience, and Walvax Biotechnology Co., Ltd.
Based on type, pneumococcal conjugate vaccine (PCV) is expected to maintain its dominant (more than half of the market share in 2017) position during the analysis period as it is been widely prescribed as compared to pneumococcal polysaccharide vaccine (PPV).
Based on product, the Prevnar 13 segment held the major market share in 2017 and is expected to dominate the market throughout the forecast period, owing to the wide usage and its efficiency in pneumonia prevention.
Based on distribution channel, the distribution partner companies segment held majority of the market share in 2017, owing to the wide coverage of the private entities. This segment is expected to dominate the market during the forecast period due to majority of private vaccines purchases which are comparatively expensive are distributed from these companies. Hence, the distribution partner companies hold larger share.
Based on sector, the private sector dominates the overall market for pneumonia vaccines and is expected to dominate the market throughout the forecast period due to the higher prices of the vaccine in the private market.
For more information and discount on this report, ask your query at: https://www.reportocean.com/industry-verticals/sample-request?report_id=43233
Major highlights of the Table of Contents of the study:
- Market Overview & Summary
- Market Dynamics
- Market Share Analysis
- PORTERS Analysis
- PESTEL Analysis
- Value-chain Analysis
Why purchase this report
- The report would provide an in-depth analysis of the current and future market trends
- Analysis of both global, regional and country lever markets
- Key strategic initiatives are taken by major players operating in the market along with ranking analysis for the key players
- Analysis based on historical information along with the current trends to estimate the future of the market
- Analysis of the impact of constantly changing global market scenarios on the market
Get in Touch with Us:
Address: Classic Tower, Rajnagar Extension, Ghaziabad, 201017 – India
Tel: +1 888 212 3539 (US – TOLL FREE)